Dr. Rita M. Schultz, D.O.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 275
Licensed in Texas since 2003, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license L7168 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St David's Medical Center Austin, TX
- St David's South Austin Medical Center Austin, TX
Medical groups
- South Austin Family Practice Clinic, PLLC (63 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 275
- Services billed
- 1,252
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 198 | 136 |
| Annual alcohol misuse screening, 5 to 15 minutes | 172 | 172 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 170 | 170 |
| Annual depression screening, 5 to 15 minutes | 156 | 156 |
| Administration of influenza virus vaccine | 52 | 51 |
| Administration of pneumococcal vaccine | 52 | 52 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 51 | 51 |
| Influenza vaccine split virus, preservative free | 49 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 46 | 44 |
| Advance care planning, first 30 minutes | 42 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 78 payments worth $1,139 in total to this clinician.
| Novo Nordisk Inc | $289 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $264 |
| Amgen Inc. | $154 |
| Lilly USA, LLC | $147 |
| AbbVie Inc. | $70.84 |
| Pfizer Inc. | $58.38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $55.01 |
| GlaxoSmithKline, LLC. | $42.53 |
| Food and Beverage | $1,125 |
|---|---|
| Education | $13.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 14, 2025 | Education in-kind | $6.65 |
| Lilly USA, LLC Jul 30, 2025 | Education in-kind | $6.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,701 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.